Catherine Sarret

Catherine Sarret

Auto-generated profile, based on publicly available information

Catherine Sarret

Departments of Pediatrics and Medical Genetics University Hospital of Clermont‐Ferrand Clermont‐Ferrand France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2019 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
PDF file
GRGanaelle Remerand
Ganaelle Remerand
OBOdile Boespflug‐Tanguy
Odile Boespflug‐Tanguy
DTDavide Tonduti
Davide Tonduti
RTRenaud Touraine
Renaud Touraine
DRDiana Rodriguez
Diana Rodriguez
RGRMLX/AHDS Study Group
RMLX/AHDS Study Group
The aim of the study was to redefine the phenotype of Allan–Herndon–Dudley syndrome (AHDS), which is caused by mutations in the SLC16A2 gene that encodes the brain transporter of thyroid hormones. Clinical phenotypes, brain imaging, thyroid hormone profiles, and genetic data were compared to the existing literature. Twenty‐four males aged 11 months to 29 years had a mutation in SLC16A2, including 12 novel mutations and five previously described mutations. Sixteen patients presented with profound developmental delay, three had severe intellectual disability with poor language and walking with an aid, four had moderate intellectual disability with language and walking abilities, and one had mild intellectual disability with hypotonia. Overall, eight had learned to walk, all had hypotonia, 17 had spasticity, 18 had dystonia, 12 had choreoathetosis, 19 had hypomyelination, and 10 had brain atrophy. Kyphoscoliosis (n=12), seizures (n=7), and pneumopathies (n=5) were the most severe complications. This study extends the phenotypic spectrum of AHDS to a mild intellectual disability with hypotonia. Developmental delay, hypotonia, hypomyelination, and thyroid hormone profile help to diagnose patients. Clinical course depends on initial severity, with stable acquisition after infancy; this may be adversely affected by neuro‐orthopaedic, pulmonary, and epileptic complications.What this paper adds: Mild intellectual disability is associated with SLC16A2 mutations. A thyroid hormone profile with a free T3/T4 ratio higher than 0.75 can help diagnose patients. Patients with SLC16A2 mutations present a broad spectrum of neurological phenotypes that are also observed in other hypomyelinating disorders. Axial hypotonia is a consistent feature of Allan–Herndon–Dudley syndrome and leads to specific complications.

1 January 2013 in Surgical Neurology International
Verified
Journal Article
Open access
JLJean-Jacques Lemaire
Jean-Jacques Lemaire
HNHachemi Nezzar
Hachemi Nezzar
LSLaurent Sakka
Laurent Sakka
YBYves Boirie
Yves Boirie
DFDenys Fontaine
Denys Fontaine
ASAntonioDe Salles
AntonioDe Salles
The human hypothalamus is a small deeply located region placed at the crossroad of neurovegetative, neuroendocrine, limbic, and optic systems. Although deep brain stimulation techniques have proven that it could be feasible to modulate these systems, targeting the hypothalamus and in particular specific nuclei and white bundles, is still challenging. Our goal was to make a synthesis of relevant topographical data of the human hypothalamus, under the form of magnetic resonance imaging maps useful for mastering its elaborated structure as well as its neighborhood. As from 1.5 Tesla, Inversion-Recovery sequence allows locating the hypothalamus and most of its components. Spotting hypothalamic compartments is possible according to specific landmarks: the anterior commissure, the mammillary bodies, the preoptic recess, the infundibular recess, the crest between the preoptic and the infundibular recesses, the optical tract, the fornix, and the mammillo-thalamic bundle. The identification of hypothalamus and most of its components could be useful to allow the quantification of local pathological processes and to target specific circuitry to alleviate severe symptoms, using physical or biological agents.

1 January 2022 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
SMSilvia Masnada
Silvia Masnada
CSCatherine Sarret
Catherine Sarret
CAClara Eleonora Antonello
Clara Eleonora Antonello
AFAla Fadilah
Ala Fadilah
HKHeiko Krude
Heiko Krude
DTDavide Tonduti
Davide Tonduti

19 January 2016 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
PDF file
CSCatherine Sarret
Catherine Sarret
JLJean‐Jacques Lemaire
Jean‐Jacques Lemaire
DTDavide Tonduti
Davide Tonduti
ASAnna Sontheimer
Anna Sontheimer
JCJérôme Coste
Jérôme Coste
OBOdile Boespflug‐Tanguy
Odile Boespflug‐Tanguy

23 July 2019 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
CSCatherine Sarret
Catherine Sarret
ZAZahra Ashkavand
Zahra Ashkavand
EPEvan Paules
Evan Paules
IDImen Dorboz
Imen Dorboz
PPPeter Pediaditakis
Peter Pediaditakis
SKSergey Krupenko
Sergey Krupenko
Neuro-ichthyotic syndromes are a group of rare genetic diseases mainly associated with perturbations in lipid metabolism, intracellular vesicle trafficking, or glycoprotein synthesis. Here, we report a patient with a neuro-ichthyotic syndrome associated with deleterious mutations in the ALDH1L2 (aldehyde dehydrogenase 1 family member L2) gene encoding for mitochondrial 10-formyltetrahydrofolate dehydrogenase. Using fibroblast culture established from the ALDH1L2-deficient patient, we demonstrated that the enzyme loss impaired mitochondrial function affecting both mitochondrial morphology and the pool of metabolites relevant to β-oxidation of fatty acids. Cells lacking the enzyme had distorted mitochondria, accumulated acylcarnitine derivatives and Krebs cycle intermediates, and had lower ATP and increased ADP/AMP indicative of a low energy index. Re-expression of functional ALDH1L2 enzyme in deficient cells restored the mitochondrial morphology and the metabolic profile of fibroblasts from healthy individuals. Our study underscores the role of ALDH1L2 in the maintenance of mitochondrial integrity and energy balance of the cell, and suggests the loss of the enzyme as the cause of neuro-cutaneous disease.

1 December 2020 in Archives de Pédiatrie
Verified
Journal Article
Closed access
SLSuzie Lefebvre
Suzie Lefebvre
CSC. Sarret
C. Sarret